CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE

Pamiparib, an investigational, oral PARP 1/2 inhibitor, demonstrated preclinical brain penetration and synergistic cytotoxicity with TMZ. We report updated safety and antitumor data for pamiparib plus RT and/or TMZ in ND-GBM or R/R-GBM (SNO 2019, ACTR-39). This dose-escalation/expansion study includ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Piotrowski, Anna, Puduvalli, Vinay, Wen, Patrick, Colman, Howard, Campian, Jian, Pearlman, Michael, Butowski, Nicholas, Cloughesy, Timothy, Battiste, James, Glass, Jon, Schiff, David, van den Bent, Martin, Walbert, Tobias, Ahluwalia, Manmeet, Badruddoja, Michael, Kalra, Amandeep, Pelham, Robert, Zhang, Kathy, Wood, Katie, Weller, Michael, Shih, Kent
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650450/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.205
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi